Effect of menopause and different combined estradiol-progestin regimens onbasal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels

Objective: To determine the effects of menopause and three different formul ations of E-2 plus medroxyprogesterone acetate on serum concentrations of b asal and growth hormone-releasing hormone (GHRH)stimulated growth hormone ( GH), insulin-like growth factor-1 (IGF-1), insulin-like growth factor bindi ng protein (IGFBP)-1, IGFBP-3, insulin, and C peptide. Design: Prospective, controlled trial. Setting: Menopausal outpatient clinic at an academic tertiary care hospital . Patient(s): Nineteen postmenopausal women with different menopausal ages. S eventeen premenopausal women were included as controls. Intervention(s): Oral estrogen (E-2 valerate, 2 mg/d) or transdermal estrog en (50-mu g or 100-mu g E-2 patch) was administered for 8 weeks. Medroxypro gesterone acetate (5 mg/d) was administered during weeks 3, 4, 7, and 8 of each protocol. Blood samples were collected before treatment and after the completion of each protocol from postmenopausal women, and on cycle days 6- 8 from premenopausal women. Main Outcome Measure(s): Levels of GH, IGF-1, IGFBP-1, IGFBP-3, insulin, an d C peptide. Result(s): Basal GH levels were negatively correlated with age in premenopa usal women but not in postmenopausal women. The area under the GHRH-induced GH curve decreased in older postmenopausal women after the oral estrogen p rotocol. Levels of IGF-1 diminished after the oral E-2 protocol in postmeno pausal women. Conclusion(s): The administration of oral, but not transdermal, E-2 plus me droxyprogesterone acetate at the usual clinical doses used in postmenopausa l women decreased IGF-1 levels and the response of GH to GHRH in older wome n. No substantial changes were detected in IGFBP-1, IGFBP-3, insulin, or C peptide levels. (Fertil Steril(R) 1999,71.261-7. (C) 1999 by American Socie ty for Reproductive Medicine.).